Skip to main content

Table 1 Clinicopathological characteristics and expression profiles of IL30 and SOCS3 in prostate cancer patients included in the “Prostate Adenocarcinoma TCGA PanCancer collection”

From: CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality

Variables

N

IL30 expression

SOCS3 expression

High

n (%)

Low

n (%)

High

n (%)

Low

n (%)

Age

41–50

35

1 (3)

34 (97)

32 (91)

3 (9)

51–60

187

4 (2)

183 (98)

186 (99)

1 (1)

61–70

235

10 (4)

225 (96)

225 (96)

10 (4)

71–80

37

1 (3)

36 (97)

34 (92)

3 (8)

Total

494

16 (3)

478 (97)

477 (97)

17 (3)

Gleason score

6

43

0 (0)

43 (100)

41 (95)

2 (5)

7

242

5 (2)

237 (98)

236 (98)

6 (2)

8

68

4 (6)

64 (94)

64 (94)

4 (6)

9

136

7 (5)

129 (95)

131 (96)

5 (4)

10

5

0 (0)

5 (100)

5 (100)

0 (0)

Total

494

16 (3)

478 (97)

477 (97)

17 (3)

Tumor size

pT2a

13

1 (8)

12 (92)

12 (92)

1 (8)

pT2b

10

1 (10)

9 (90)

10 (100)

0 (0)

pT2c

164

5 (3)

159 (97)

159 (97)

5 (3)

pT3a

157

5 (3)

152 (97)

150 (96)

7 (4)

pT3b

133

4 (3)

129 (97)

129 (97)

4 (3)

pT4

10

0 (0)

10 (100)

10 (100)

0 (0)

NA

7

0 (0)

7 (100)

7 (100)

0 (0)

Total

494

16 (3)

478 (97)

477 (97)

17 (3)

Lymph node status

pN0

343

8 (2)

335 (98)

333 (97)

10 (3)

pN1

78

4 (5)

74 (95)

76 (97)

2 (3)

NA

73

4 (5)

69 (95)

68 (93)

5 (7)

Total

494

16 (3)

478 (97)

477 (97)

17 (3)

Stage

I

10

1 (10)

9 (90)

9 (90)

1 (10)

II

130

4 (3)

126 (97)

129 (99)

1 (1)

III

199

3 (2)

196 (98)

191 (96)

8 (4)

IV

78

4 (5)

74 (95)

76 (97)

2 (3)

NA

77

4 (5)

73 (95)

72 (94)

5 (6)

Total

494

16 (3)

478 (97)

477 (97)

17 (3)